Abstract
Pancreatic cancer is an aggressive, frequently fatal malignancy that strikes 37,000 patients annually in the U.S.A. It is poorly responsive to standard chemotherapies such as gemcitabine. Approximately 5-10% of pancreatic cancer occurs in the setting of a BRCA2 mutation. Breast and ovarian carcinomas that harbor BRCA2 mutations are susceptible to the effects of an emerging class of targeted agents, namely, poly(ADP-ribose) polymerase (PARP) inhibitors. This report describes the case of a patient with a germline BRCA2 mutation and an associated pancreatic cancer treated with iniparib (BSI-201), a PARP inhibitor, who demonstrated a complete pathologic response to this agent. This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 1417-1420 |
Number of pages | 4 |
Journal | Anticancer research |
Volume | 31 |
Issue number | 4 |
State | Published - Apr 2011 |
Keywords
- BRCA
- Chemotherapy
- Iniparib
- Pancreatic cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research